Ophthalmic Diagnostic Devices Market (2026 - 2033)

Ophthalmic Diagnostic Devices Market Summary

The global ophthalmic diagnostic devices market size was valued at USD 3.6 billion in 2025 and is projected to grow from USD 3.7 billion in 2026 to USD 4.7 billion by 2033, at a CAGR of 3.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. This growth is attributed to the growing geriatric population, prevalence of chronic diseases, and increasing awareness and screening programs.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Another primary factor for market growth is technological advancement, which has resulted in many diagnostic solutions that are more accurate, less invasive, and automated. Technological advancements in optical coherence tomography (OCT), AI-assisted retinal imaging, adaptive optics, visual evoked potential (VEP), and corneal topography are improving the early detection and monitoring of eye diseases. Portable and automated devices, including handheld fundus cameras and wearable visual field-testing systems, are also improving examination efficiency and access to diagnostic services.

To learn more about this report, Download Free Sample Report

In 2026, Heidelberg Engineering introduced an updated SPECTRALIS software release, strengthening its multimodal retinal imaging capabilities. The update features OCT angiography scanning speeds of up to 250 kHz, enhanced active eye tracking, and a Green Autofluorescence Module to support detailed retinal examination. Faster scanning can help reduce image acquisition time, while eye-tracking technology helps maintain scan alignment and improve image consistency. The additional autofluorescence capability supports visualization of retinal and macular structures, assisting clinicians in evaluating conditions such as age-related macular degeneration and other retinal disorders. These improvements highlight the growing focus on faster, more precise, and integrated ophthalmic diagnostic technologies, supporting continued innovation in retinal imaging systems.

AI-enabled diagnosis is also advancing. In July 2026, the U.S. FDA cleared iPredict-DR, a diabetic retinopathy detection device developed by iHealthScreen, demonstrating continued progress in automated retinal screening. Additionally, in October 2026, Topcon Healthcare and RadiusXR introduced InspirePRO, a wearable visual field-testing system designed to support glaucoma assessment across different stages of disease. These developments illustrate the growing role of integrated imaging, AI-assisted analysis, and portable diagnostics in ophthalmic care.

The aging population and the growing incidence of chronic diseases are other factors affecting market growth that influence ophthalmic diagnosis. Aging affects vision by gradually impairing the structure and function of the eye, leading to conditions such as cataracts and age-related macular degeneration (AMD). These issues reduce transparency in the lens and damage the macula area of the retina, ultimately leading to distorted and blurry vision. Regular eye examinations employing advanced ophthalmic diagnostic equipment, such as optical coherence tomography (OCT) and fundus imaging, can facilitate the timely detection and monitoring of age-related disorders.

Additional risk factors like oxidative stress, inflammation, and genetic predisposition can result in more rapid vision loss among older adults. For instance, in 2024, a review published in Progress in Retinal and Eye Research highlighted those age-related changes in the lens and retina, such as cataract formation and macular degeneration, increase the need for precise ophthalmic diagnostic imaging. Advanced devices like Optical Coherence Tomography (OCT) and fundus cameras enable early detection and monitoring, helping healthcare providers manage ocular health more effectively in older adults.

Adding to this, chronic health conditions like diabetes and hypertension affect age-related vision health tremendously. In diabetes, sustained high blood sugar can result in diabetic retinopathy, while uncontrolled blood pressure may lead to hypertensive retinopathy. Both conditions damage the blood vessels found in the retina and can cause diseases such as macular edema, glaucoma, or even permanent vision loss if not managed properly.

Source: NIH, National Eye Institute

Furthermore, the World Health Organization (WHO) estimates that at least 2.2 billion people worldwide experience some aspect of vision impairment, with chronic eye diseases such as diabetic retinopathy, cataracts, and glaucoma being significant contributors. This increasing prevalence of vision impairment reflects the urgent need for prompt diagnoses and tracking through advanced ophthalmic diagnostic devices.

Ophthalmic diagnostic devices are also seeing market growth with the expansion of eye care facilities on a global scale. An increased numbers of hospitals, clinics, and specialty eye centers ensure advanced diagnostic and treatment services are available to urban and rural populations. For instance, the National Library of Medicine states that an increase in the eye care infrastructure and eye care professionals is needed in underserved areas. This increase aids in accommodating the demand for early detection and management of eye diseases such as cataracts, glaucoma, and diabetic retinopathy.

Market Dynamics

Market Concentration & Characteristics

The market for ophthalmic diagnostic devices is seeing robust growth propelled by technological innovations, an increase in the prevalence of eye disorders, and a growing awareness of maintaining eye health. Healthcare Asia Magazine states that the market's growth is consistent and gradual, due to new developments in diagnostic technologies and increasing medical tourism (especially for cataract surgery). The FDA states that regulatory science and research programs are fast-tracking the development of safe and effective ophthalmic devices, further instilling confidence and growing the market. Companies such as Johnson & Johnson Vision Care, Alcon Vision LLC, and Carl Zeiss Meditec AG are positioning themselves as major players by launching new and improved diagnostic systems and expanding their international presence using regulatory expertise.

Innovation in ophthalmic diagnostic devices is increasingly driven by AI-assisted retinal screening, ultra-widefield imaging, automated image acquisition, and integrated diagnostic platforms. These technologies improve image analysis, support earlier disease detection, and streamline clinical workflows. For instance, in September 2026, Topcon Healthcare announced innovations including the GAIA ultra-widefield retinal imaging device, offering a 209-degree field of view in a single capture, alongside updates to its Maestro3 diagnostic platform and IMAGEnet 7 imaging software. These developments demonstrate the industry's shift toward wider retinal visualization, automated diagnostics, and connected eye care workflows.

To learn more about this report, Download Free Sample Report

Another example is the launch of Oku Digital Health in October 2026, originating from Topcon Healthcare. Its connected care solution combines retinal imaging, clinical data, and AI-enabled decision support to help identify potential ocular and systemic disease risks and guide patient referrals. This illustrates how ophthalmic diagnostics are expanding beyond standalone imaging equipment toward data-driven screening and coordinated care.

Strategic collaborations are helping ophthalmic diagnostic companies integrate AI technologies with imaging equipment and expand access to screening. For example, in January 2026, Optomed partnered with Aireen to integrate Aireen's AI algorithm for diabetic retinopathy screening with Optomed's Lumo handheld fundus camera. The combined solution received approval for integration in the European Union, supporting the commercial deployment of AI-assisted retinal screening in primary care, ophthalmology clinics, and mobile screening programs.

In another example, Heidelberg Engineering and RetinAI expanded their collaboration in September 2026 to make RetinAI Discovery for Clinics available through Heidelberg Engineering's direct sales organization in selected markets. The solution combines ophthalmic imaging, connected data management, and AI-supported analysis, enabling clinicians to access and assess patient imaging data within a more integrated workflow. Such collaborations allow diagnostic equipment manufacturers to complement hardware sales with digital capabilities and strengthen their competitive position in connected ophthalmic care.

Ophthalmic diagnostic devices are strictly regulated to ensure safety, efficacy, and quality. In the U.S., 21 CFR Part 886 classifies devices by risk and sets requirements for diagnostic tools like ophthalmic cameras, adaptometers, and ocular esthesiometers, ensuring thorough evaluation before market entry. In India, the CDSCO, under the Medical Devices Rules, 2017, mandates registration, compliance documentation, and licensing for Class C and D devices, guiding manufacturers through a clear regulatory pathway. These regulations minimize patient risk, build trust in ophthalmic technologies, and uphold ethical standards in the global medical device market.

New technologies are replacing traditional ophthalmic diagnostic devices. Non-invasive instruments for Dry Eye Disease, like TearLab, Keratograph 5M, LipiView II, and LacryDiag, allow precise tear film and ocular surface evaluation without invasive methods. Likewise, biosensing contact lens sensors provide real-time monitoring of intraocular pressure (IOP), tear biomarkers, and other ocular parameters so that continuous and personalized disease monitoring can occur for patients. In addition to traditional diagnostics, these devices assist with early detection and patient convenience, thus producing hopeful alternatives in ophthalmology.

Growth in the ophthalmic diagnostic devices market is supported by companies expanding their regional presence, distribution networks, and clinical support capabilities. North America and Europe benefit from established healthcare infrastructure and advanced eye care facilities, while Asia-Pacific offers growth opportunities through rising eye disease prevalence and expanding access to ophthalmic services. For instance, in July 2026, Lumibird Medical completed its acquisition of Malaysian distributor BIZ MEDIC Sdn Bhd and launched Lumibird Medical Southeast Asia, establishing a regional hub in Kuala Lumpur. The hub supports sales, servicing, clinical training, and distribution of its Quantel Medical, Optotek Medical, and Ellex portfolios across Southeast Asia. This expansion strengthens local customer support and access to ophthalmic technologies, including diagnostic and therapeutic laser systems. 

Analyst Perspective

The ophthalmic diagnostic devices market is driven by the growing prevalence of eye disorders, increasing demand for early diagnosis, and advancements in ocular imaging technologies. Rising cases of cataracts, glaucoma, diabetic retinopathy, and age-related macular degeneration are encouraging healthcare providers to adopt advanced diagnostic solutions. Innovations in optical coherence tomography, fundus imaging, artificial intelligence, and automated examination systems are improving diagnostic accuracy and clinical efficiency. Meanwhile, expanding eye care infrastructure, growing awareness of routine eye examinations, and increasing investments in ophthalmology services are creating market opportunities. However, high equipment costs, limited access to specialized care, and affordability constraints remain significant challenges.

Product Insights

The optical coherence tomography (OCT) scanners segment accounted for the largest market share of 23.1% in 2025. This is attributed to factors such as providing high-resolution, cross-sectional, and three-dimensional imaging of ocular tissues, essential in diagnosing and monitoring such conditions as glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD). Recent technological advancements have enabled the integration of OCT with robotic systems, significantly enhancing the accuracy and consistency of imaging for precise evaluation of delicate and complex ocular structures. In addition, imaging speed and resolution improvements are expanding OCT’s clinical applications, allowing ophthalmologists to perform intricate diagnostic procedures more efficiently. These innovations contribute to OCT’s position as one of the fastest-growing ophthalmic diagnostic device market segments.

The ophthalmoscopes market segment is witnessing significant growth at a CAGR of 3.8%. Modern ophthalmoscopes allow excellent visualization of the retina and optic nerve, which enhances detection and monitoring of glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and more. The market has shifted from traditional handheld manual ophthalmoscopes to digital, smart, scan-dependent devices incorporating enhanced imaging, illumination, and connectivity to improve diagnostic accuracy. For example, in January 2025, the Lynx Ophthalmoscope received FDA clearance and CE marking to use an advanced, portable device to simplify retinal imaging and clinical workflows to provide better eye care efficiently and accurately.

Function Insights

The imaging-based diagnostic devices segment accounted for the largest market share in 2025, driven by the growing acceptance of advanced retinal imaging technologies. These technologies, including optical coherence tomography (OCT), fundus photography, and fluorescein angiography, help better visualize retinal structures in detail and in real time, providing early diagnosis and accurate reporting of diseases resulting from conditions like age-related macular degeneration (AMD). The advent of integrating multiple imaging methods has further facilitated ophthalmologists in examining and reporting the progression of the disease and accurately examining treatment. The increased reliance on imaging-based diagnostic tools for early diagnosis and follow-up of disease progression signifies the importance of imaging technology in contemporary ophthalmic care.

The functional/vision assessment devices segment is witnessing significant growth during the forecast period. due to the widespread adoption of digital refractors, autorefractors, phoropters, and retinal cameras in clinics. These devices provide accurate and efficient measurements of refractive errors and corneal curvature, and they retain health, surpassing traditional manual assessments. Their routine use enhances patient evaluations, offering near real-time results and improving clinical efficiency, reliability, and diagnostic accuracy. This trend reflects increasing trust and utilization of device-based visual/ function assessments, driving the segment’s rapid growth in the ophthalmic diagnostic devices market.

Procurement/Ownership Insights

The purchase-based/capital acquisition segment accounted for the largest market share of in 2025, fueled by a surge in investments for companies creating and supplying essential ophthalmic devices. Recent transactions highlight the considerable inward capital to bolster the expansion of and innovation in diagnostic and surgical devices, like Warburg Pincus’ acquisition of a controlling interest in Appasamy Associates. Appasamy is a leading manufacturer of ophthalmic devices and intraocular lenses (IOLs) in India with a diverse end customer base of clinics and hospitals, which indicates a solid market for ophthalmic diagnostic and surgical devices. Investing in companies like Appasamy enables scaling operations, research, and distribution capabilities.

The subscription-based model segment is expected to grow significantly during the forecast period. The increasing acceptance of patient membership plans in optometry and ophthalmology practices is helping to drive the adoption of subscription models. With membership plans, patients pay a monthly or annual fee for a full range of vision care services, including routine exams, eyewear discounts, and personalized care. The membership model improves patient engagement, produces predictable revenue in the clinic, and reduces reliance on traditional insurance reimbursement. Programs like BoomCloud allow practices to manage and scale membership plans, providing greater administrative ease and efficiency.

Application Insights

The cataract segment is expected to have the largest market share of the ophthalmic diagnostic devices market in 2025, fueled by growing global demand for enhanced vision care and the opportunity to benefit from surgical intervention. Reasons such as advancements in surgical techniques, legitimatization of unique intraocular lenses (IOLs), and changes in the use of artificial intelligence to increase accuracy and precision serve as accelerators for this trend. The geriatric population and the growing prevalence of cataract-related vision impairment are notable contributors.

The refractive disorders segment is expected to grow significantly during the forecast period due to the increasing prevalence of refractive disorders, particularly myopia. Advanced surgical technologies and techniques enhance the safety and effectiveness of procedures like laser-assisted in situ keratomileusis (LASIK) and Photorefractive Keratectomy (PRK), leading to higher patient satisfaction and broader adoption. This trend underscores the growing demand for corrective vision solutions and the expanding role of refractive surgery in modern ophthalmology.

End-use Insights

The hospitals & eye clinics segment is expected to have the largest market share in 2025, due to the growing uptake of new advanced diagnostic and surgical technologies in the clinical area. Eye-Q's installation of an Advanced Customized LASIK machine in Rewari increases access to high-precision vision correction for patients in the local area. Furthermore, the insourcing plans mentioned by Elective UK for hospitals and clinics to bring in a specialized ophthalmic team improve the efficiency of diagnostic assessments, reduce patient waiting times, and expand the overall service capacity. These components position hospitals and eye clinics to become the fastest-growing end-use segment.

To learn more about this report, Download Free Sample Report

The academic & research laboratories segment is expected to grow significantly during the forecast period. Academic and research laboratories have been receiving financing to conduct ophthalmic treatment. For example, the Shenzhen Eye Hospital, located in China, has acquired much funding for its research projects in intelligent ophthalmology. The publication "Development and Research Status of Intelligent Ophthalmology in China" discusses some progress in intelligent ophthalmology, primarily emphasizing the roles of academic and research laboratories in areas such as the detection of diabetic retinopathy, fundus image analysis, and the design of medical artificial intelligence products.

Regional Insights

The North American Ophthalmic Diagnostic devices market is witnessing significant growth, it is driven by a fast-growing aging population and an increased prevalence of chronic eye disease, such as diabetic retinopathy patients, associated with increasingly poor lifestyles and stressful living. Strict regulatory systems and dynamic reimbursement models further drive demand. New devices must meet high safety, efficacy, and compliance standards yearly. The introduction of advanced imaging devices (e.g., optical coherence tomography, retinal cameras), AI-assisted diagnostics, and mobile non-invasive diagnostic devices, all to satisfy clinical and patient demands, is also seeing increased growth and adoption. With all these factors converging at once demographic issues, the growing burden of chronic disease, regulations, and medical technology, the market is expanding steadily regarding the range of novel products and clinical use.

To learn more about this report, Download Free Sample Report

The U.S. ophthalmic diagnostic devices market has increased due to the significant burden of eye disorders, increasing the need for advanced and accurate ophthalmic diagnostic devices. According to the CDC, over 7 million Americans are experiencing vision loss or blindness. Furthermore, nearly 90 million adults aged 40 and older live with some kind of vision or eye problem. An estimated 20.5 million of these aged 40s have cataracts alone, which remain the leading cause of impairment. Several other eye conditions, including diabetic eye disease, glaucoma, and macular degeneration, are also among the leading causes of impairment. Many of them progress mimicking the eye's wear and tear, leading to the importance of early detection. The need for innovative and accurate diagnostic technology is growing to monitor eye health, inform treatment plans efficiently, and ultimately improve long-term patient outcomes nationwide.

Europe Ophthalmic Diagnostic Devices Market Trends

The European market for ophthalmic diagnostic devices is witnessing significant growth, and the drive toward integrated, person-centered eye and vision care is boosting the demand for advanced ophthalmic diagnostic devices. The World Health Organization (WHO) emphasizes that eye care services should be accessible, available, affordable, and high-quality for diverse populations. This goal relies on accurate and efficient diagnostic testing. Increasing awareness of the prevalence and impact of vision disorders and government initiatives to strengthen research, monitoring, and evidence-based eye care further support the adoption of innovative diagnostic technologies. By integrating eye care into national health systems and promoting universal coverage, European countries are fostering an enabling environment for ophthalmic diagnostic devices, facilitating early detection, timely treatment, and improved patient outcomes.

The UK Ophthalmic Diagnostic Device market is steadily growing. Eye disorders, such as diabetic retinopathy and age-related macular degeneration (AMD), represent significant health concerns within the UK, contributing to a growing demand for advanced ophthalmic diagnostic devices. Diabetic retinopathy, a complication of diabetes, can develop unnoticed and lead to vision loss if not detected; therefore, regular screening is beneficial. AMD is characterized by a decline of the central retina, primarily affecting those over 50. Dry AMD is a slow progression; however, wet AMD can lead to rapid vision loss. Early detection and timely diagnosis during routine eye examinations are critical in preserving vision.

Source: UK Eye Care Data Hub

The France ophthalmic diagnostic devices market is witnessing substantial growth, due to the convergence of technology, public-private partnerships, and government support that continues to drive demand for these devices. For instance, ZEISS recently released its AI-enabled devices, including CIRRUS PathFinder, to improve diagnostic accuracy and workflow efficiency for retina care. Furthermore, the French government's reimbursement of HOYA's MiYOSMART myopia control lenses for children aged 5-16 is a bold public health initiative to improve myopia treatment. These advances represent meaningful collaboration to advance eye care services in France and to further facilitate the uptake of new diagnostic technology.

The ophthalmic diagnostic devices market in Germany is witnessing significant growth,driven by the rising incidence of eye diseases, such as cataracts, glaucoma, and age-related macular degeneration. The advanced healthcare setting and well-established healthcare institutions facilitate the adoption of devices capable of accurate, early detection of retinal disease using diagnostic technologies such as optical coherence tomography (OCT). Public health reports have presented alarming trends related to visual impairment, which has increased the need for robust screening and monitoring practices. These variables are driving the adoption of innovative ophthalmic diagnostic devices across the country.

Asia Pacific Ophthalmic Diagnostic Devices Market Trends

The Asia Pacific region is experiencing a growing burden of visual impairment due to increasing prevalence rates, particularly among adults of working age. Increases in visual impairment have been associated with refractive errors, cataracts, and age-related eye diseases. Public health studies and advanced epidemiological modeling have identified regional variation, with East and South Asia projected to have the highest burden by 2040. The increasing prevalence indicates an urgent need for early detection, screening programs, and effective intervention. These factors contribute to the region's capacity requirements for comprehensive eye care services and new ophthalmic diagnostic solutions.

Japan’s ophthalmic diagnostic devices market is witnessing a rise due to its aging population, which is projected to exceed 10% of those aged 80 and above as of 2023. Japan is seeing an increasing demand for ophthalmic diagnostic devices, due to increasing eye health concerns (i.e., myopia), which emphasizes the need for advanced eye health diagnostic devices to allow for precision in diagnostics. Japan's advanced medical device technology sector, government support, and healthcare advancements all facilitate the wider adoption of these next-generation tools and technologies throughout Japan.

The ophthalmic diagnostic devices market in China is rapidly growing. This growth is due to several key factors, such as the increasing prevalence of eye diseases among the population, especially in elderly individuals in suburban Shanghai, which is ultimately driving the need for better eye care. Secondly, technological advancements support this growth, with new devices like the SMART Phaco-Vitrectomy Machine that combine cataract and retinal surgery, improving diagnostic and surgical efficiency. Additionally, regulatory approvals, such as Eyebright Medical receiving a Class III certificate from the National Medical Products Administration for its phakic intraocular lens, facilitate the adoption of advanced ophthalmic devices. Together, these drivers are boosting the growth of ophthalmic diagnostic devices across China.

India's Ophthalmic Diagnostic devices market is experiencing a rising demand for ophthalmic diagnostic devices driven by two primary factors. The first factor is the increased incidence of eye diseases, such as cataracts, glaucoma, refractive errors, and diabetic retinopathy, for which the need for improved diagnostic equipment is increasing. The second factor is expanding healthcare infrastructure, notably through building Vision Centers in rural and underserved settings, which provides access to device availability for early detection and treatment. These developments combine to drive the utilization and proliferation of ophthalmic diagnostic devices in India.

Latin America Ophthalmic Diagnostic Devices Market Trends

The ophthalmic diagnostic devices market in Latin America is expanding due to the rising prevalence of eye disorders, including cataracts and vision impairment, particularly in at-risk populations, like older adults. The growing burden of eye disorders requires early detection and optimal management. Advancements in healthcare infrastructure and the availability of eye care services are supporting the demand for ophthalmic diagnostic devices. These factors continue contributing to the growth of ophthalmic diagnostic devices across the region.

Brazil's ophthalmic diagnostic devices marketis experiencing significant growth, addressing the country’s substantial burden of vision disorders. The Brazilian Council of Ophthalmology (Conselho Brasileiro de Oftalmologia, CBO) has highlighted the rising prevalence of diabetes and an aging population as key drivers of demand for early detection tools. Hospitals and private clinics across major cities such as São Paulo, Rio de Janeiro, and Belo Horizonte are adopting technologies like optical coherence tomography (OCT), fundus cameras, and visual field analyzers to improve early diagnosis of glaucoma and retinal diseases.

Middle East & Africa Ophthalmic Diagnostic Devices Market Trends

In the Middle East & Africa, the ophthalmic diagnostic devices market is witnessing steady expansion, driven by several converging factors. The prevalence of vision loss is rising in both urban and rural populations, particularly among older adults, due to cataracts, glaucoma, uncorrected refractive errors, and diabetic retinopathy. The demographic shift toward aging also contributes significantly to demand. For instance, blindness increases sharply after age 60 in many countries in Sub-Saharan Africa and the Arabian Peninsula.

The ophthalmic devices market in Saudi Arabia is expected to grow in the forecast period. Improved technologies such as optical coherence tomography (OCT) and non-mydriatic fundus cameras drive the market's overall growth. Research indicates that OCT allows for accurate early detection of glaucoma, and fundus cameras enable general practitioners to identify diabetic retinopathy screening in rural settings. With the increasing rates of eye disease, these technologies continue to drive demand for more advanced diagnostic devices, thus increasing access and accuracy and the market's overall size.

Kuwait's Ophthalmic Diagnostic Devices marketis expected to grow steadily with increased healthcare investments, rising awareness of eye health, and a growing number of new healthcare facilities. In addition, increasing government action to improve access to eye care and the rising instances of eye-related illness will drive additional growth in demand for modern ophthalmic diagnostic equipment. As hospitals and clinics continue to modernize their ophthalmic departments, there should be greater uptake of diagnostic technologies, such as Optical Coherence Tomography (OCT) and fundus cameras, which will aid in continued growth.

Key Companies & Market Share Insights/Industry Insights

The ophthalmic diagnostic devices market is highly competitive, with key players such as Johnson & Johnson Vision Care, Alcon Vision LLC, and Carl Zeiss Meditec AG. The major companies undertake various organic and inorganic strategies such as product introduction, collaborations, and regional expansion to serve the unmet needs of their customers.

Key Ophthalmic Diagnostics Devices Companies

The following key companies have been profiled for this study on the ophthalmic diagnostics devices market.

• Carl Zeiss Meditec AG

• Nidek Co. Ltd

• TOPCON Corporation

• Haag-Streit Group

• Canon, Inc.

• Heidelberg Engineering GmbH

• Visionix USA Inc.

• Reichert Technologies (AMETEK, Inc.)

• Hoya Corporation

• Ophtecs Corporation

Recent Developments

• In September 2026, NIDEK introduced the RSD-1 Duo OCT/Fundus Camera, AFC-1 non-mydriatic fundus camera, and EyeLink Eye Care Data Management Platform. The launch combines retinal imaging and data management with automated image acquisition, supporting more efficient screening and diagnostic workflows.

• In September 2025, OpZira Inc. was established as a spin-off from LumiThera after Alcon's acquisition. OpZira now offers two ophthalmic diagnostic products: the AdaptDx Pro, a portable dark adaptometer utilizing AI and precision eye-tracking to assess retinal adaptation, and the NOVA Vision Testing System, which employs Visual Evoked Potential (VEP) and Electroretinography (ERG) to evaluate the visual and neuro-visual pathways. Both devices are currently available in the United States, with the ERG module pending U.S. availability.

• In February 2024, ARPA-H awarded funding to a project led by Washington University in St. Louis to develop a compact and affordable optical coherence tomography (OCT) device. This shoebox-sized platform aims to make eye disease diagnostics more accessible and cost-effective by miniaturizing optical components and enabling faster, high-quality retinal imaging.

Global Ophthalmic Diagnostic Devices Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the ophthalmic diagnostic devices market report on the basis of product, function, procurement/ownership, application, end-use, and region:

• Product Outlook (Revenue, USD Unit, 2021 - 2033)

  • Optical Coherence Tomography Scanners

  • Fundus Cameras

  • Perimeters/Visual Field Analysers

  • Autorefractors and Keratometers

  • Ophthalmic Ultrasound Imaging Systems

    • Ophthalmic A-Scan Ultrasound

    • Ophthalmic B-Scan Ultrasound

    • Ophthalmic Ultrasound Biomicroscopes

    • Ophthalmic Pachymeters

  • Tonometers

  • Slit Lamps

  • Phoropters

  • Wavefront Aberrometers

  • Optical Biometry Systems

  • Ophthalmoscopes

  • Lensmeters

  • Corneal Topography Systems

  • Specular Microscopes

  • Retinoscopes

• Function Outlook (Revenue, USD Unit, 2021 - 2033)

  • Imaging-Based Diagnostic Devices

  • Functional/Vision Assessment Devices

  • Basic Clinical Examination Devices

• Procurement/Ownership Outlook (Revenue, USD Unit, 2021 - 2033)

  • Purchase-based/Capital Acquisition

  • Rental/Leasing Model

  • Subscription-based Model

  • Hybrid Models

• Application Outlook (Revenue, USD Unit, 2021 - 2033)

  • Cataract

  • Vitreo-retinal Disorders

  • Glaucoma

  • Refractive Disorders

• End-use Outlook (Revenue, USD Unit, 2021 - 2033)

  • Hospitals & Eye Clinics

  • Academic & Research Laboratories

  • Others

• Regional Outlook (Revenue, USD Unit, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The ophthalmic diagnostic devices market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each ophthalmic diagnostic devices segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations